Charles River Laboratories International, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Charles River Laboratories International, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $633 of operating cash. Higher than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$633Over the last 3 years, every $100 of reported profit came with $633 of operating cash.
Higher than 98% of Healthcare companies in United States.
Self-Funding Ratio
2.8×Over the last 3 years its own operating cash covered its investment spending (capex) 2.8 times.
Higher than 78% of Healthcare companies in United States.
Cash Locked Ratio
$21For every $100 of sales, $21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $20 tied up three years earlier.
Less money tied up than 55% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+1% / -6%In 3 years sales changed by +1% while total assets changed by -6%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
56%Of every $100 the company owns, $56 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 72% of Healthcare companies in United States.
Tangible Net Worth Ratio
2%Of every $100 of net worth, $2 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 72% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Charles River Laboratories International, Inc. made a loss over the last year. Charles River Laboratories International, Inc. owes $0.62 for every $1 it owns. Charles River Laboratories International, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCharles River Laboratories International, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.86The share price is 5.86 times Charles River Laboratories International, Inc.'s book value per share, higher than 76% of Healthcare companies in United States.
Market cap
$16.6 BThe total market value of all of Charles River Laboratories International, Inc.'s shares at today's price (share price × number of shares), larger than 93% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$2.8 BWhat Charles River Laboratories International, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$58.95Net worth divided by the number of shares. The share price of $345.37 is 5.9 times this, which is the P/B above.
Return on equity (ROE)
-7.5%Charles River Laboratories International, Inc. lost 7.5% of its shareholders' money over the last year, higher than 73% of Healthcare companies in United States.
Owes vs Owns
0.62×Charles River Laboratories International, Inc. owes $0.62 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Dividend yield
NoneCharles River Laboratories International, Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Profit growth
LossCharles River Laboratories International, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-3.6%Charles River Laboratories International, Inc. lost $4 for every $100 of revenue.
Interest cover
3.7×Charles River Laboratories International, Inc.'s operating profit covered its interest costs 3.7 times in the year to Dec 2025.
Cash vs debt
Net debtCharles River Laboratories International, Inc. had $2.4 B more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Charles River Laboratories International, Inc.: $16.6 B ÷ $2.8 B (30 Jun 2026) = 5.9.
What is Charles River Laboratories International, Inc.'s return on equity?
Charles River Laboratories International, Inc. lost 7.5% of its shareholders' money over the last year, higher than 73% of Healthcare companies in United States.
How much does Charles River Laboratories International, Inc. owe compared with what it owns?
Charles River Laboratories International, Inc. owes $0.62 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Does Charles River Laboratories International, Inc. pay a dividend?
No. Charles River Laboratories International, Inc. does not currently pay a dividend.
Is Charles River Laboratories International, Inc.'s revenue growing?
Revenue fell 1% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.